My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 157

    1.

    Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease.

    Abuirmeileh A, Harkavyi A, Lever R, Biggs CS, Whitton PS.

    J Neuroinflammation. 2007 Jul 21;4:19.PMID: 17659087 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The CRF-like peptide urocortin greatly attenuates loss of extracellular striatal dopamine in rat models of Parkinson's disease by activating CRF(1) receptors.

    Abuirmeileh A, Harkavyi A, Kingsbury A, Lever R, Whitton PS.

    Eur J Pharmacol. 2009 Feb 14;604(1-3):45-50. Epub 2008 Nov 13.PMID: 19026631 [PubMed - indexed for MEDLINE]Related articles

    3.

    The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.

    Abuirmeileh A, Lever R, Kingsbury AE, Lees AJ, Locke IC, Knight RA, Chowdrey HS, Biggs CS, Whitton PS.

    Eur J Neurosci. 2007 Jul;26(2):417-23.PMID: 17650114 [PubMed - indexed for MEDLINE]Related articles

    4.

    The CRF-like peptide urocortin produces a long-lasting recovery in rats made hemiparkinsonian by 6-hydroxydopamine or lipopolysaccharide.

    Abuirmeileh A, Harkavyi A, Kingsbury A, Lever R, Whitton PS.

    J Neurol Sci. 2008 Aug 15;271(1-2):131-6. Epub 2008 May 27.PMID: 18508084 [PubMed - indexed for MEDLINE]Related articles

    5.

    Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.

    Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS.

    J Neuroinflammation. 2008 May 21;5:19.PMID: 18492290 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.

    Kageyama K, Kimura R, Suga S, Ogawa Y, Suda T, Wakui M.

    Peptides. 2006 Jul;27(7):1814-9. Epub 2006 Feb 28.PMID: 16513211 [PubMed - indexed for MEDLINE]Related articles

    7.

    Endogenous expression and in vitro study of CRF-related peptides and CRF receptors in the rat gastric antrum.

    Porcher C, Peinnequin A, Pellissier S, Meregnani J, Sinniger V, Canini F, Bonaz B.

    Peptides. 2006 Jun;27(6):1464-75. Epub 2005 Dec 6.PMID: 16337313 [PubMed - indexed for MEDLINE]Related articles

    8.

    Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.

    Zorrilla EP, Reinhardt LE, Valdez GR, Inoue K, Rivier JE, Vale WW, Koob GF.

    J Pharmacol Exp Ther. 2004 Sep;310(3):1027-34. Epub 2004 Apr 28.PMID: 15115804 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    The effects of corticoptropin-releasing factor and the urocortins on striatal dopamine release induced by electrical stimulation-an in vitro superfusion study.

    Bagosi Z, Jászberényi M, Bujdosó E, Telegdy G.

    Neurochem Res. 2006 Feb;31(2):209-13. Epub 2006 Mar 2.PMID: 16518577 [PubMed - indexed for MEDLINE]Related articles

    10.

    Urocortins and the regulation of gastrointestinal motor function and visceral pain.

    Martinez V, Wang L, Million M, Rivier J, Taché Y.

    Peptides. 2004 Oct;25(10):1733-44. Review.PMID: 15476940 [PubMed - indexed for MEDLINE]Related articles

    11.

    rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.

    Manfredsson FP, Burger C, Sullivan LF, Muzyczka N, Lewin AS, Mandel RJ.

    Exp Neurol. 2007 Oct;207(2):289-301. Epub 2007 Jul 10.PMID: 17678648 [PubMed - indexed for MEDLINE]Related articles

    13.

    The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications.

    Gravanis A, Margioris AN.

    Curr Med Chem. 2005;12(13):1503-12. Review.PMID: 15974983 [PubMed - indexed for MEDLINE]Related articles

    14.

    Effects of urocortin 2 and 3 on motor activity and food intake in rats.

    Ohata H, Shibasaki T.

    Peptides. 2004 Oct;25(10):1703-9.PMID: 15476937 [PubMed - indexed for MEDLINE]Related articles

    16.

    Evidence supporting a role for corticotropin-releasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergic neurons.

    Staub DR, Evans AK, Lowry CA.

    Brain Res. 2006 Jan 27;1070(1):77-89. Epub 2006 Jan 3.PMID: 16403469 [PubMed - indexed for MEDLINE]Related articles

    17.

    Urocortin 2 expression in the rat gastrointestinal tract under basal conditions and in chemical colitis.

    Chang J, Hoy JJ, Idumalla PS, Clifton MS, Pecoraro NC, Bhargava A.

    Peptides. 2007 Jul;28(7):1453-60. Epub 2007 May 21.PMID: 17586086 [PubMed - indexed for MEDLINE]Related articles

    18.

    Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system.

    Hashimoto K, Nishiyama M, Tanaka Y, Noguchi T, Asaba K, Hossein PN, Nishioka T, Makino S.

    Peptides. 2004 Oct;25(10):1711-21. Review.PMID: 15476938 [PubMed - indexed for MEDLINE]Related articles

    19.

    Identification and characterization of multiple corticotropin-releasing factor type 2 receptor isoforms in the rat esophagus.

    Wu SV, Yuan PQ, Wang L, Peng YL, Chen CY, Taché Y.

    Endocrinology. 2007 Apr;148(4):1675-87. Epub 2007 Jan 11.PMID: 17218420 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system.

    Herrera AJ, Castaño A, Venero JL, Cano J, Machado A.

    Neurobiol Dis. 2000 Aug;7(4):429-47.PMID: 10964613 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Find related data

    Write to the Help Desk